Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis.
Int Urol Nephrol
; 47(10): 1679-81, 2015 Oct.
Article
in En
| MEDLINE
| ID: mdl-26347076
ABSTRACT
Hemorrhagic cystitis is a rare and severe late complication of pelvic radiation, and there is no regulatory-approved drug treatment. We present an 81-year-old man with a history of localized prostate cancer, which was treated with external beam radiation therapy and subsequently developed severe hemorrhagic radiation cystitis for which he has failed several treatments. We present the novel use of intravesical tacrolimus for the treatment of refractory radiation cystitis and gross hematuria. The patient tolerated the treatment well, and it resulted in the resolution of his gross hematuria without further consideration for formalin instillation or cystectomy and diversion. Intravesical tacrolimus is a safe, minimally invasive, and promising treatment option for radiation hemorrhagic cystitis.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Radiation Injuries
/
Tacrolimus
/
Cystitis
/
Calcineurin Inhibitors
/
Hematuria
Type of study:
Etiology_studies
Limits:
Aged80
/
Humans
/
Male
Language:
En
Journal:
Int Urol Nephrol
Year:
2015
Type:
Article
Affiliation country:
United States